 |  |
Welcome to Lycera CorpLycera is an early-stage pharmaceutical company developing first-in-class drugs to treat immune disorders. Lycera’s technology platforms include proprietary small molecules that modulate a target, which is central to cellular bioenergetics along with molecules that target the Th17 pathway. Drugs that emerge from the Lycera pipeline will represent first-in-class agents that have the potential for first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents. |
|
News & UpdatesLycera Closes $36 M Series A Financing Dr. Douglas Green, renown immunologist joins Lycera SAB |
|
QUICKLINKS |
|
|
|
||